MedTrace Logo

Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System

NCT06157567 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2025-08-22

No results posted yet for this study

Summary

This is a non-randomized, multi-center, open-label clinical trial evaluating clinical feasibility treatments with the Profound Matrix system.

Conditions

  • Skin Laxity
  • Wrinkle
  • Skin Condition

Interventions

DEVICE

Profound Matrix

Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).

Sponsors & Collaborators

  • Candela Corporation

    lead INDUSTRY

Principal Investigators

  • Konika Schallen, MD · Candela Institue for Exellence

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-24
Primary Completion
2027-05-24
Completion
2028-05-24
FDA Device
Yes

Countries

  • United States
  • Canada
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06157567 on ClinicalTrials.gov